Fig. 9: Therapeutic efficacy and systematic antitumor immune responses mechanism in EMT6-bearing mice. | Nature Communications

Fig. 9: Therapeutic efficacy and systematic antitumor immune responses mechanism in EMT6-bearing mice.

From: Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer

Fig. 9

a Schematic illustration of experimental design. Tumor growth curves of b primary tumors (***p = 0.0001, **p = 0.0041) and c bone metastatic tumors (***p = 0.0006, **p = 0.0062) after various treatments (1: PBS (+); 2: free Oxa; 3: Oxa(IV)@ZnPc; 4: Oxa(IV)@ZnPc@M; 5: BMMs + anti-PD-L1; 6: Oxa(IV)@ZnPc (+); 7: Oxa(IV)@ZnPc@M (+); 8: Oxa(IV)@ZnPc@M (+) + anti-PD-L1; 9: Oxa + anti-PD-L1; and 10: Oxa(IV)@ZnPc (+) + anti-PD-L1, “(+)” represent laser irradiation, applied for all the antitumor studies in vivo) (n = 6 individual animals). d Overall survival curves. e Body weight after various treatments (n = 6 individual animals). f Schematic illustration of experimental design of antitumor immune evaluation. g Quantitation of the percent of tumor-infiltrating CD4+T cells (***p = 0.0008, **p = 0.0095, ***p < 0.0001, *p = 0.0467). h The representative flow cytometric plots of tumor-infiltrating CD4+ T cells and CD8+ T cells (n = 4 individual animals). Quantitation of the percent of i tumor-infiltrating CD8+T cell (**p = 0.0049, ***p = 0.0004, **p = 0.0044), j intratumoral ratio of CD8+ T cells to Treg (**p = 0.0014, **p = 0.0018, *p = 0.0219), k IFN-γ within CD8+ T cells (**p = 0.0043, ***p < 0.0001, ***p < 0.0001) and l TNF-α within CD8+ T cells (**p = 0.0031, ***p = 0.0010, *p = 0.0177) (n = 4 individual animals). All data were presented as mean ± SD. Statistical significance was calculated via the unpaired two-tailed t test b, ordinary one-way ANOVA with a Tukey’s test g or Dunnett’s test c, i–l. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source data file.

Back to article page